Alessandro Toscano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alessandro Toscano has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Didier Gaston Ebo
Universiteit Antwerpen Faculteit geneeskunde en gezondheidswetenschappen
12 shared publications - Michiel Beyens
Department of Immunology, Allergology, Rheumatology, the Infla‐Med Centre of Excellence, Faculty of Medicine and Health Sciences University of Antwerp Antwerp Belgium
10 shared publications - Vito Sabato
Department of Immunology, Allergology, Rheumatology, the Infla‐Med Centre of Excellence, Faculty of Medicine and Health Sciences University of Antwerp Antwerp Belgium
10 shared publications - Christel Mertens
Immunology–Allergology–Rheumatology, Faculty of Medicine and Health Sciences Antwerp University, Hospital, Infla‐Med Centre of Excellence, Antwerp University, University of Antwerp Antwerp Belgium
8 shared publications - Jessy Elst
Universiteit Antwerpen Faculteit geneeskunde en gezondheidswetenschappen
8 shared publications - Athina Ludovica Van Gasse
Department of Pediatrics, the Infla‐Med Centre of Excellence, Faculty of Medicine and Health Sciences University of Antwerp Antwerp Belgium
6 shared publications
Latest Publications
- 7 September 2026
- Published by Taylor & Francis in Acta Clinica Belgica
- p. 1-11
GATA2: a small gene with big impact – a case report and literature review
We report the case of a patient with a de novo pathogenic germline variant causing GATA2 deficiency. GATA2 deficiency is a rare autosomal dominant inborn error of immunity caused by heterozygous lo...
- 7 September 2026
- Published by Taylor & Francis in Acta Clinica Belgica
- p. 1-11
GATA2: a small gene with big impact – a case report and literature review
We report the case of a patient with a de novo pathogenic germline variant causing GATA2 deficiency. GATA2 deficiency is a rare autosomal dominant inborn error of immunity caused by heterozygous lo...
- Open Access
- 24 July 2026
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 81 (6) , 487-500
Belgian consensus-based recommendations on the management of hospitalized patients with a penicillin allergy label
The prevalence of penicillin allergy labels varies from 10%–20% in United States (US), United Kingdom (UK) and Australian studies to 3%–6% in Belgium or the Netherlands, respectively [1,2], with hi...
- 24 July 2026
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 81 (6) , 487-500
Open AccessBelgian consensus-based recommendations on the management of hospitalized patients with a penicillin allergy label
The prevalence of penicillin allergy labels varies from 10%–20% in United States (US), United Kingdom (UK) and Australian studies to 3%–6% in Belgium or the Netherlands, respectively [1,2], with hi...
- 29 July 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (3) , 243-251
Towards an Optimal Decision Threshold for Specific I g E to r C an s 3 the Non‐Specific Lipid Transfer Protein of Cannabis sativa
Background: Cannabis allergy is increasingly reported, with Can s 3 as a major allergen. Investigations into sensitisation to Can s 3 utilise sophisticated techniques, including the cytometric bead assay and the basophil activation test. This study aims to utilise a fluorescence enzyme immunoassay to quantify sIgE to Can s 3, employing a recombinant Can s 3 protein. Methods: This study included 104 cannabis allergic patients, 20 healthy controls and 70 exposed atopic controls. Specific IgE by a fluorescence enzyme immunoassay or cytometric bead assay and the basophil activation test all used the same recombinant allergen. Two‐graph ROC curves were used to determine the clinically validated allergen‐specific cut‐off for maximal sensitivity and specificity and to facilitate direct comparison of the test performances. Results: Twenty‐two individuals were non‐responding in the basophil activation test and were excluded from all analyses involving basophil activation test results. The clinically validated cut‐off points are > 0.16 kU A /L, ≥ 0.14 kU A /L and > 5% for a fluorescence enzyme immunoassay, cytometric bead assay and basophil activation test, respectively. Utilising these thresholds, the fluorescence enzyme immunoassay exhibited a sensitivity of 72% and specificity of 74%, the cytometric bead assay demonstrated a sensitivity of 49% and specificity of 89%. In responders, the basophil activation test exhibited a sensitivity of 51% and specificity of 82%. Remarkably, low positive fluorescence enzyme immunoassay results, particularly below 0.35 kU A /L, are negative for both cytometric bead assay and basophil activation test. Conversely, utilising the conventional threshold of > 0.35 kU A /L, the sIgE a fluorescence enzyme immunoassay results exhibited greater congruence with those of the cytometric bead assay and basophil activation test. Conclusion: This study underscores the complexity of establishing an optimal decision threshold for the sIgE rCan s 3 fluorescence enzyme immunoassay and indicates that the clinically validated decision cut‐off may not always represent the most efficacious approach.
- 29 July 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (3) , 243-251
Towards an Optimal Decision Threshold for Specific I g E to r C an s 3 the Non‐Specific Lipid Transfer Protein of Cannabis sativa
Background: Cannabis allergy is increasingly reported, with Can s 3 as a major allergen. Investigations into sensitisation to Can s 3 utilise sophisticated techniques, including the cytometric bead assay and the basophil activation test. This study aims to utilise a fluorescence enzyme immunoassay to quantify sIgE to Can s 3, employing a recombinant Can s 3 protein. Methods: This study included 104 cannabis allergic patients, 20 healthy controls and 70 exposed atopic controls. Specific IgE by a fluorescence enzyme immunoassay or cytometric bead assay and the basophil activation test all used the same recombinant allergen. Two‐graph ROC curves were used to determine the clinically validated allergen‐specific cut‐off for maximal sensitivity and specificity and to facilitate direct comparison of the test performances. Results: Twenty‐two individuals were non‐responding in the basophil activation test and were excluded from all analyses involving basophil activation test results. The clinically validated cut‐off points are > 0.16 kU A /L, ≥ 0.14 kU A /L and > 5% for a fluorescence enzyme immunoassay, cytometric bead assay and basophil activation test, respectively. Utilising these thresholds, the fluorescence enzyme immunoassay exhibited a sensitivity of 72% and specificity of 74%, the cytometric bead assay demonstrated a sensitivity of 49% and specificity of 89%. In responders, the basophil activation test exhibited a sensitivity of 51% and specificity of 82%. Remarkably, low positive fluorescence enzyme immunoassay results, particularly below 0.35 kU A /L, are negative for both cytometric bead assay and basophil activation test. Conversely, utilising the conventional threshold of > 0.35 kU A /L, the sIgE a fluorescence enzyme immunoassay results exhibited greater congruence with those of the cytometric bead assay and basophil activation test. Conclusion: This study underscores the complexity of establishing an optimal decision threshold for the sIgE rCan s 3 fluorescence enzyme immunoassay and indicates that the clinically validated decision cut‐off may not always represent the most efficacious approach.
Flow Cytometry‐Assisted Analyses of Individual Human Basophils, Mast Cells and T Cells in the Diagnosis of Immediate Drug Hypersensitivity: A Review
Immediate drug hypersensitivity reactions (IDHRs) pose significant diagnostic challenges, often requiring potentially hazardous drug challenge testing (DCT). Flow cytometry‐based cellular tests including the basophil activation test (BAT), the mast cell activation test (MAT) and the T cell activation test (TAT) offer promising alternatives to reduce DCT reliance. While these tests are still in development, they demonstrate potential to compete with skin tests by providing superior diagnostic performance and improved patient safety by reducing the need for DCT. Furthermore, it is encouraging that these flow cytometry‐based tests are also suitable for challenging populations, such as children. Despite requiring specialised infrastructure, these tests have the potential to be cost‐effective when performed in reference centres and may offer unique mechanistic insights into immediate drug hypersensitivity reactions. However, further research is needed to validate their reliability, address pharmaceutical‐specific testing considerations, and potentially integrate them into clinical guidelines.
Flow Cytometry‐Assisted Analyses of Individual Human Basophils, Mast Cells and T Cells in the Diagnosis of Immediate Drug Hypersensitivity: A Review
Immediate drug hypersensitivity reactions (IDHRs) pose significant diagnostic challenges, often requiring potentially hazardous drug challenge testing (DCT). Flow cytometry‐based cellular tests including the basophil activation test (BAT), the mast cell activation test (MAT) and the T cell activation test (TAT) offer promising alternatives to reduce DCT reliance. While these tests are still in development, they demonstrate potential to compete with skin tests by providing superior diagnostic performance and improved patient safety by reducing the need for DCT. Furthermore, it is encouraging that these flow cytometry‐based tests are also suitable for challenging populations, such as children. Despite requiring specialised infrastructure, these tests have the potential to be cost‐effective when performed in reference centres and may offer unique mechanistic insights into immediate drug hypersensitivity reactions. However, further research is needed to validate their reliability, address pharmaceutical‐specific testing considerations, and potentially integrate them into clinical guidelines.
- 26 July 2024
- Published by Wiley in Contact Dermatitis
- Vol. 91 (6) , 513-515
Allergic contact dermatitis mimicking angioedema of the lips and eyelids from a vegan ‘HEMA‐free’ gel nail polish containing acrylates and isocyanates
- 26 July 2024
- Published by Wiley in Contact Dermatitis
- Vol. 91 (6) , 513-515
Allergic contact dermatitis mimicking angioedema of the lips and eyelids from a vegan ‘HEMA‐free’ gel nail polish containing acrylates and isocyanates
- 9 July 2024
- Published by Elsevier in Revue Française d'Allergologie
- Vol. 64 (5)
Propriétés allergiques et activatrices de MRGPRX2 des médicaments : vers un algorithme mécanistique résolutif
- 9 July 2024
- Published by Elsevier in Revue Française d'Allergologie
- Vol. 64 (5)
Propriétés allergiques et activatrices de MRGPRX2 des médicaments : vers un algorithme mécanistique résolutif
- 3 July 2024
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 54 (10) , 760-762
IgE‐Mediated Mast Cell Responses to Rocuronium: A Matter of Protonation Status
- 3 July 2024
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 54 (10) , 760-762
IgE‐Mediated Mast Cell Responses to Rocuronium: A Matter of Protonation Status
- 26 December 2023
- Published by Wiley in Contact Dermatitis
- Vol. 90 (4) , 429-431
Cross‐reactivity to lincomycin in patients with maculopapular exanthem to clindamycin: A case series
- 26 December 2023
- Published by Wiley in Contact Dermatitis
- Vol. 90 (4) , 429-431
Cross‐reactivity to lincomycin in patients with maculopapular exanthem to clindamycin: A case series